Basic Principles in Gynecologic Radiotherapy

Clinical Gynecologic Oncology: Eighth Edition

Volumn , Issue , 2012, Pages 659-680

  Yashar, Catheryn M ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902036663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-07419-3.00023-0     Document Type: Chapter

References (85)

1. Khan FM The Physics of Radiation Therapy 1994, Williams & Wilkins, Baltimore. 2nd ed.
2. Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003, 56:1154.
3. Bokemeyer C, Lampe C, Heneka M, et al. Paclitaxel-induced radiation recall dermatitis. Ann Oncol 1996, 7:755.
4. Brizel DM Phase II Randomized trial of Amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000, 18:3339.
5. Budd GT, Ganapathi R, Adelstein DJ, et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer 1997, 80:1134.
6. Buntzel J Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Ann Onc 1998, 9:505.
7. Calabro-Jones PM Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79-171 cells incubated in medium containing WR-2721. Int J Radiat Biol 1985, 47:23.
8. Chen L, Trujillo K, Sung P, Tomkinson AE Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase. J Biol Chem 2000, 275:2196.
9. Committee on the Biological Effects of Ionizing Radiation The effects on populations of exposure to low levels of ionizing radiation 1990, National Academy of Sciences/National Research Council, Washington DC.
10. Davidson DE Biological characteristics of some improved radioprotectors. Radiation Sensitizers 1980, Masson: 309, New York. Anonymous (Ed.).
11. Dizdaroglu M Measurement of radiation-induced damage to DNA at the molecular level. Int J Radiat Biol 1992, 61:175.
12. Doll R, Wakeford R Risk of childhood cancer from fetal irradiation. Br J Radiol 1997, 70:130.
13. Dynan WS, Yoo S Interaction of Ku protein and DNA-dependent protein catalytic subunit with nucleic acids. Nucleic Acids Res 1998, 26:1551.
14. Eguchi-Kasai K, Kosaka T, Sato K, Kaneko I Reparability of DNA double-strand breaks and radiation sensitivity in five mammalian cell lines. Int J Radiat Biol 1991, 59:97.
15. Grigsby PW, Siegel BA, Dehdashti F, Mutch DG Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int J Radiat Oncol Biol Phys 2003, 55:907.
16. Haber JE The many interfaces of Mre11. Cell 1998, 95:583-586.
17. Hall EJ, Astor M, Bedford J, et al. Basic Radiobiology. Am J Clin Oncol 1988, 11:220.
18. Hall EJ Radiobiology for the Radiologist 2000, Lippincott Williams & Wilkins, Philadelphia. 5th ed.
19. Hasselle MD, Rose BS, Kochanski JD, et al. Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the Cervix. Int J Radiat Oncol Biol Phys 2010 Aug 12, [epub ahead of print].
20. Horsman MR, Overgaard J Overcoming tumour radiation resistance resulting from acute hypoxia. Eur J Cancer 1992, 28A:2084.
21. Hortobagyi GN Anthracyclines in the treatment of cancer. An overview. Drugs 1997, 54(Suppl 4):1.
22. Jacobs AJ, Faris C, Perez CA, et al. Short-term persistence of carcinoma of the uterine cervix after radiation. An indicator of long-term prognosis. Cancer 1986, 57:944.
23. Kemp G Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 1996, 14:2101.
24. Kerr JFR, Harmon BV Definition and incidence of apoptosis: An historical perspective. Apoptosis: The molecular basis of cell death 1991, 5. Cold Harbor Laboratory Press, Cold Spring Harbor, NY. L.D. Tomei, F.O. Cope (Eds.).
25. Kneale GW, Stewart AM Prenatal x rays and cancers: further tests of data from the Oxford Survey of Childhood Cancers. Health Phys 1986 Sep, 51:369.
26. Koukourakis MI Subcutaneous administration of Amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 2000, 18:2226.
27. Koukourakis MI, Tsoutsou PG, Abatzoglou I, et al. Postoperative accelerated radiotherapy with cytoprotection followed by three-dimensional conformal boost in patients with early endometrial/cervical cancer. Tumori 2009, 95:455.
28. Lee KJ, Huang J, Takeda Y, Dynan WS DNA ligase IV and XRCC4 form a stable mixed tetramer that functions synergistically with other repair factors in a cell-free end-joining system. J Biol Chem 2000, 275:34787.
29. Leskov KS, Criswell T, Antonio S, et al. When X-ray-inducible proteins meet DNA double strand break repair. Sem Rad Onc 2001, 11:352.
30. Liang Y, Messer K, Rose BS, et al. Impact of bone marrow radiation dose on acute hematologic toxicity in cervical cancer: principal component analysis on high dimensional data. Int J Radiat Oncol Biol Phys 2010, 78:912.
31. Lim K, Small W, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys 2010 May 14, [Epub ahead of print].
32. Liu T Use of radiation with or without WR-2721 in advanced rectal cancer. Cancer 1992, 69:2820.
33. Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003, 14:1086.
34. Maluf FC, Leiser AL, Aghajanian C, et al. Phase II study of tirapazamine plus cisplatin in patients with advanced or recurrent cervical cancer. Int J Gynecol Cancer 2006, 16:1165.
35. Munro TR The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat Res 1970, 42:451.
36. Munro TR The site of the target region for radiation-induced mitotic delay in cultured mammalian cells. Radiat Res 1970, 44:747.
37. Ohhnishi ST In vitro study on the antioxidant activities of amifostine (WR-2721). Proceedings of the American Association of. Cancer Research 1992, 33:419.
38. Otake M, Schull WJ Radiation-related brain damage and growth retardation among the prenatally exposed atomic bomb survivors. Int J Radiat Biol 1998 Aug, 74:159.
39. Paull TT, Gellert M Nbs1 potentiates ATP-driven DNA unwinding and endonuclease cleavage by the Mre11/Rad50 complex. Genes Dev 1999, 13:1276.
40. Preston DL, Pierce DA, Shimizu Y, et al. Effect of recent changes in atomic bomb survivor dosimetry on cancer mortality risk estimates. Radiat Res 2004, 162:377.
41. Preston DL, Shimizu Y, Pierce DA, et al. Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 2003, 160:381.
42. Preston DL, Pierce DA, Shimizu Y, et al. Dose response and temporal patterns of radiation-associated solid cancer risks. Health Phys 2003, 85:43.
43. Schull WJ The children of atomic bomb survivors: a synopsis. J Radiol Prot 2003, 23:369.
44. Rose PG Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma. Semin Oncol 1996, 23(4 Suppl 8):83.
45. Takahashi I Clinical study of the radioprotective effects of amifostine (YM-08310, WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys 1986, 12:935.
46. Tanaka Y Clinical experiences of chemical radiation protection in tumor radiotherapy in Japan. Radiation Sensitizers 1980, Masson, New York, p. 421. L.W. Brady (Ed.).
47. Thompson LH, Suit HD Proliferation kinetics of x-irradiated mouse L cells studied WITH TIME-lapse photography. II. Int J Radiat Biol Relat Stud Phys Chem Med 1969, 15:347.
48. 35S-Labeled WR-2721 in normal and malignant tissues of the mouse. Radiation Research 1976, 68:284.
49. Ward JF Mechanisms of DNA repair and their potential modification for radiotherapy. Int J Radiat Oncol Biol Phys 1986, 12:1027.
50. Washburn LC Prediction of the effective radioprotective dose of WR-2721 in humans through an interpecies tissue distribution study. Radiation Research 1976, 66:100.
51. Yoo S, Dynan WS Geometry of a complex formed by double strand break repair proteins at a single DNA end: recruitment of DNA-PKcs induces inward translocation of Ku protein. Nucleic Acids Res 1999, 27:4679.
52. Yuhas JM Active versus passive absorption kinetics as the basis for selective protection of normal tissues by S-2-(3-Aminopropylamino)-ethylphosphorothionic acid. Cancer Research 1980, 40:1519.
53. Yuhas JM The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clinical Trials 1980, 3:211.
54. Ferrigno R, Nishimoto IN, Ribeiro Dos Santos Novaes PE, et al. Comparison of low and high dose rate brachytherapy in the treatment of uterine cervix cancer: Retrospective analysis of two sequential series. Int J Radiat Oncol Biol Phys 2005, 62:1108.
55. Fletcher GH Textbook of Radiotherapy 1980, Lea & Febiger, Philadelphia. 3rd ed.
56. Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix: a randomized trial. Cancer 2002, 94:117.
57. Kim WC, Kim GE, Suh CO, Loh JJ High versus low dose rate intracavitary irradiation for adenocarcinoma of the uterine cervix. Jpn J Clin Oncol 2001 Sep, 31:432.
58. Kucera H, Potter R, Knocke TH, et al. High-dose versus low-dose rate brachytherapy in definitive radiotherapy of cervical cancer. Wien Klin Wochenschr 2001, 113:58.
59. Lertsanguansinchai P, Lertbutsayanukul C, Shotelersuk K, et al. Phase III randomized trial comparing LDR and HDR brachytherapy in treatment of cervical carcinoma. Int J Radiat Oncol Biol Phys 2004, 59:1424.
60. Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000, 48:201.
61. Nag S, Erickson B, Parikh S, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 2000, 48:779.
62. Patel FD, Sharma SC, Negi PS, et al. Low dose rate vs. high dose rate brachytherapy in the treatment of carcinoma of the uterine cervix: a clinical trial. Int J Radiat Oncol Biol Phys 1994, 28:335.
63. Petereit DG, Sarkaria JN, Potter DM, Schink JC High-dose-rate versus low-dose-rate brachytherapy in the treatment of cervical cancer: analysis of tumor recurrence-the University of Wisconsin experience. Int J Radiat Oncol Biol Phys 1999, 45:1267.
64. Small W, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. Int J Radiat Oncol Biol Phys 2007, 68:1801.
65. Britten RA, Peters LJ, Murray D biological factors influencing the RBE of neutrons: implications for their past, present, and future use in radiotherapy. Radiat Res 2001, 156:125.
66. Wenz F, Welzel G, Blank E, et al. Intraoperative radiotherapy as a boost during breast-conserving surgery using low-kilovoltage X-rays: the first 5 years of experience with a novel approach. Int J Radiat Oncol Biol Phys 2010, epub ahead of print.
67. Beriwal S, Heron DE, Kim H, et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys 2006, 64:1395.
68. Choi CW, Cho CK, Yoo SY, et al. Image-guided stereotactic body radiation therapy in patients with isolated para-aortic lymph node metastases from uterine cervical and corpus cancer. Int J Radiat Oncol Biol Phys 2009, 74:147.
69. del Carmen MG, Eisner B, Willet CG, Fuller AF Intraoperative radiation therapy in the management of gynecologic and genitourinary malignancies. Surg Oncol Clin N Am 2003, 12:1031.
70. Dimopoulos JC, Pötter R, Lang S, et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol 2009, 93:311.
71. Gemignani ML, Alektiar KM, Leitao M, et al. Radical surgical resection and high-dose intraoperative radiation therapy (HDR-IORT) in patients with recurrent gynecologic cancers. Int J Radiat Oncol Biol Phys 2001, 50:687.
72. Georg P, Lang S, Dimopoulos JC, et al. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys 2010 Apr 10, (epub ahead of print).
73. Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol 2005, 74:235.
74. Hsieh CH, Wei MC, Lee HY, et al. Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomotherapy. Radiat Oncol 2009, 4:62.
75. Jürgenliemk-Schulz IM, Tersteeg RJ, Roesink JM, et al. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol 2009, 93:322.
76. Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: relationship to prognosis. J Clin Oncol 2010, 28:2108.
77. Kidd EA, Siegel BA, Dehdashti F, et al. Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer. Int J Radiat Oncol Biol Phys 2009 Oct 30, [Epub ahead of print].
78. Kirisits C, Pötter R, Lang S, et al. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2005, 62:901.
79. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002, 52:1330.
80. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol 2006, 78:67.
81. Roeske JC, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2000, 48:1613.
82. Tanderup K, Dietmar G, Pötter R, et al. Adaptive management of cervical cancer radiotherapy. Semin Rad Oncol 2010, 20:121.
83. van der Zee J, Gonzalez GD The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002, 18:1.
84. van der Zee J, Gonzalez GD, van Rhoon GC, et al. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000, 355:1119.
85. Vasanthan A, Mitsumori M, Park JH, et al. Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency. Int J Radiat Oncol Biol Phys 2005, 61:145.